MCI patients in Europe

Medication and comorbidities. the DESCRIPA study

Magda Tsolaki, Vasileios Papaliagkas, Giovanni Frisoni, Roy Jones, Jacques Touchon, Luiza Spiru, Bruno Vellas, Frans Verhey, Bengt Winblad, Pieter Jelle Visser, DESCRIPA Study Group

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: The main objective of the present study was to investigate the prevalence and type of medication taken by MCI patients in the DECRIPA cohort. A secondary objective was to assess the cognitive function of these patients and the relationship between the results of neuropsychometric tests and medication use. Materials and Methods: We selected 880 subjects (375 males, 505 females) who were older than 55 years without obvious causes of cognitive impairment. A complete history was obtained for all patients. In addition, demographical data were collected and several factors were studied, including the types and dosages of the medications taken. Comparisons between groups were statistically analyzed in relation to the number of medications. Results: Most patients (85.7%, n=754) were taking at least one medication during the study period. The median (interquartile range-IQ) number of medications per participant was 3 (1-5), whereas 40% of the patients took at least 4 medications. The types of medications that were most often taken were cardiovascular drugs (62.0%), antidepressants (16.8%), sedatives (14.6%), thyroid drugs (10.0%) and anti-diabetic drugs (7.6%). Conclusion: On average, MCI patients take three medications for the prevention or treatment of an av\erage of two medical conditions. The most prevalent types of medications were cardiovascular drugs, antidepressants, sedatives and thyroid drugs. Significant differences in the number of medications taken were observed for gender and age.

Original languageEnglish
Pages (from-to)1407-1413
Number of pages7
JournalCurrent Alzheimer Research
Volume13
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Comorbidity
Cardiovascular Agents
Hypnotics and Sedatives
Antidepressive Agents
Thyroid Gland
Pharmaceutical Preparations
Cognition
History
Therapeutics

Keywords

  • Alzheimer’s disease
  • Anticholinergic drugs. co-morbidity
  • Medication
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Tsolaki, M., Papaliagkas, V., Frisoni, G., Jones, R., Touchon, J., Spiru, L., ... DESCRIPA Study Group (2016). MCI patients in Europe: Medication and comorbidities. the DESCRIPA study. Current Alzheimer Research, 13(12), 1407-1413. https://doi.org/10.2174/1567205013666160603002704

MCI patients in Europe : Medication and comorbidities. the DESCRIPA study. / Tsolaki, Magda; Papaliagkas, Vasileios; Frisoni, Giovanni; Jones, Roy; Touchon, Jacques; Spiru, Luiza; Vellas, Bruno; Verhey, Frans; Winblad, Bengt; Visser, Pieter Jelle; DESCRIPA Study Group.

In: Current Alzheimer Research, Vol. 13, No. 12, 01.12.2016, p. 1407-1413.

Research output: Contribution to journalArticle

Tsolaki, M, Papaliagkas, V, Frisoni, G, Jones, R, Touchon, J, Spiru, L, Vellas, B, Verhey, F, Winblad, B, Visser, PJ & DESCRIPA Study Group 2016, 'MCI patients in Europe: Medication and comorbidities. the DESCRIPA study', Current Alzheimer Research, vol. 13, no. 12, pp. 1407-1413. https://doi.org/10.2174/1567205013666160603002704
Tsolaki, Magda ; Papaliagkas, Vasileios ; Frisoni, Giovanni ; Jones, Roy ; Touchon, Jacques ; Spiru, Luiza ; Vellas, Bruno ; Verhey, Frans ; Winblad, Bengt ; Visser, Pieter Jelle ; DESCRIPA Study Group. / MCI patients in Europe : Medication and comorbidities. the DESCRIPA study. In: Current Alzheimer Research. 2016 ; Vol. 13, No. 12. pp. 1407-1413.
@article{ce0952ca1fe8437fbd34ddbbcffd901f,
title = "MCI patients in Europe: Medication and comorbidities. the DESCRIPA study",
abstract = "Objectives: The main objective of the present study was to investigate the prevalence and type of medication taken by MCI patients in the DECRIPA cohort. A secondary objective was to assess the cognitive function of these patients and the relationship between the results of neuropsychometric tests and medication use. Materials and Methods: We selected 880 subjects (375 males, 505 females) who were older than 55 years without obvious causes of cognitive impairment. A complete history was obtained for all patients. In addition, demographical data were collected and several factors were studied, including the types and dosages of the medications taken. Comparisons between groups were statistically analyzed in relation to the number of medications. Results: Most patients (85.7{\%}, n=754) were taking at least one medication during the study period. The median (interquartile range-IQ) number of medications per participant was 3 (1-5), whereas 40{\%} of the patients took at least 4 medications. The types of medications that were most often taken were cardiovascular drugs (62.0{\%}), antidepressants (16.8{\%}), sedatives (14.6{\%}), thyroid drugs (10.0{\%}) and anti-diabetic drugs (7.6{\%}). Conclusion: On average, MCI patients take three medications for the prevention or treatment of an av\erage of two medical conditions. The most prevalent types of medications were cardiovascular drugs, antidepressants, sedatives and thyroid drugs. Significant differences in the number of medications taken were observed for gender and age.",
keywords = "Alzheimer’s disease, Anticholinergic drugs. co-morbidity, Medication, Mild cognitive impairment",
author = "Magda Tsolaki and Vasileios Papaliagkas and Giovanni Frisoni and Roy Jones and Jacques Touchon and Luiza Spiru and Bruno Vellas and Frans Verhey and Bengt Winblad and Visser, {Pieter Jelle} and {DESCRIPA Study Group}",
year = "2016",
month = "12",
day = "1",
doi = "10.2174/1567205013666160603002704",
language = "English",
volume = "13",
pages = "1407--1413",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - MCI patients in Europe

T2 - Medication and comorbidities. the DESCRIPA study

AU - Tsolaki, Magda

AU - Papaliagkas, Vasileios

AU - Frisoni, Giovanni

AU - Jones, Roy

AU - Touchon, Jacques

AU - Spiru, Luiza

AU - Vellas, Bruno

AU - Verhey, Frans

AU - Winblad, Bengt

AU - Visser, Pieter Jelle

AU - DESCRIPA Study Group

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objectives: The main objective of the present study was to investigate the prevalence and type of medication taken by MCI patients in the DECRIPA cohort. A secondary objective was to assess the cognitive function of these patients and the relationship between the results of neuropsychometric tests and medication use. Materials and Methods: We selected 880 subjects (375 males, 505 females) who were older than 55 years without obvious causes of cognitive impairment. A complete history was obtained for all patients. In addition, demographical data were collected and several factors were studied, including the types and dosages of the medications taken. Comparisons between groups were statistically analyzed in relation to the number of medications. Results: Most patients (85.7%, n=754) were taking at least one medication during the study period. The median (interquartile range-IQ) number of medications per participant was 3 (1-5), whereas 40% of the patients took at least 4 medications. The types of medications that were most often taken were cardiovascular drugs (62.0%), antidepressants (16.8%), sedatives (14.6%), thyroid drugs (10.0%) and anti-diabetic drugs (7.6%). Conclusion: On average, MCI patients take three medications for the prevention or treatment of an av\erage of two medical conditions. The most prevalent types of medications were cardiovascular drugs, antidepressants, sedatives and thyroid drugs. Significant differences in the number of medications taken were observed for gender and age.

AB - Objectives: The main objective of the present study was to investigate the prevalence and type of medication taken by MCI patients in the DECRIPA cohort. A secondary objective was to assess the cognitive function of these patients and the relationship between the results of neuropsychometric tests and medication use. Materials and Methods: We selected 880 subjects (375 males, 505 females) who were older than 55 years without obvious causes of cognitive impairment. A complete history was obtained for all patients. In addition, demographical data were collected and several factors were studied, including the types and dosages of the medications taken. Comparisons between groups were statistically analyzed in relation to the number of medications. Results: Most patients (85.7%, n=754) were taking at least one medication during the study period. The median (interquartile range-IQ) number of medications per participant was 3 (1-5), whereas 40% of the patients took at least 4 medications. The types of medications that were most often taken were cardiovascular drugs (62.0%), antidepressants (16.8%), sedatives (14.6%), thyroid drugs (10.0%) and anti-diabetic drugs (7.6%). Conclusion: On average, MCI patients take three medications for the prevention or treatment of an av\erage of two medical conditions. The most prevalent types of medications were cardiovascular drugs, antidepressants, sedatives and thyroid drugs. Significant differences in the number of medications taken were observed for gender and age.

KW - Alzheimer’s disease

KW - Anticholinergic drugs. co-morbidity

KW - Medication

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84995920185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995920185&partnerID=8YFLogxK

U2 - 10.2174/1567205013666160603002704

DO - 10.2174/1567205013666160603002704

M3 - Article

VL - 13

SP - 1407

EP - 1413

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 12

ER -